Evaluation of a Booster Dose of Pneumococcal Vaccine Formulations in Young Adults

Inclusion Criteria: * Subjects who the investigator believes will comply with the requirements of the protocol should be enrolled in the study. * A male or female between, and including, 18 and 41 years old at the time of vaccination. * Subjects who previously participated in the study NCT00707798 and received one of the two investigational GSK2189242A vaccine formulations during the primary study. * Written informed consent obtained from the subject. * Free of obvious health problems as established by medical history, clinical examination and clinical laboratory assessment before entering into the study. * Female subjects of non-childbearing potential (defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause) may be enrolled in the study. * Female subjects of childbearing potential may be enrolled in the study, if the subject: * has practiced adequate contraception for 30 days prior to vaccination, and * has a negative pregnancy test on the day of vaccination, and * has agreed to continue adequate contraception during the entire treatment period and for 2 months after vaccination. Exclusion Criteria: * Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the vaccination, or planned use during the study period. * Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to vaccination. * Planned administration/administration of a vaccine not foreseen by the study protocol during the period starting 30 days prior to the vaccination and ending one month (minimum 30 days) after vaccination. * Administration of any pneumococcal vaccine other than the study vaccine during the period between end of study NCT00707798 and study vaccination. * Bacterial pneumonia within the period between end of study NCT00707798 and study vaccination. * Invasive pneumococcal disease (IPD) within the period between end of study NCT00707798 and study vaccination. * Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection (no laboratory testing required). * History of thrombocytopenia or bleeding disorder. * Anaphylactic reaction following the previous administration of the vaccine or history of reactions or allergic disease likely to be exacerbated by any component of the vaccine. * Current serious neurologic or mental disorders. * Inflammatory processes such as known chronic active infections (e.g. Hepatitis B, C). * All past or current malignancies (excluding non-melanic skin cancer) and lymphoproliferative disorders. * Acute disease at the time of enrolment/vaccination. * Fever at the time of vaccination. Fever is defined as temperature \>= 37.5°C on oral setting. * Physical examination positive for acrocyanosis, jaundice, splenomegaly. * Acute or chronic, clinically significant anaemia, pulmonary, cardiovascular, hematologic, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests, at the discretion of the investigator * Administration of immunoglobulins and/or any blood products within the three months preceding vaccination or planned administration during the study period. * Pregnant or lactating female. * Female planning to become pregnant or planning to discontinue contraceptive precautions. * History of chronic alcohol consumption and/or drug abuse. * Other conditions that the principal investigator judges may interfere with study findings.